Fat mass and obesity associated (FTO) gene influences skeletal muscle phenotypes in non-resistance trained males and elite rugby playing position by Heffernan, S M et al.
This work has been submitted to NECTAR, the Northampton Electronic Collection
of Theses and Research.
Article
Title: Fat mass and obesity associated (FTO) gene influences skeletal muscle
phenotypes in non­resistance trained males and elite rugby playing position
Creators: Heffernan, S. M., Stebbings, G. K., Kilduff, L. P., Erskine, R. M., Day, S. H.,
Morse, C. I., McPhee, J. S., Cook, C. J., Vance, B., Ribbans, W. J., Raleigh, S. M.,
Roberts, C., Bennett, M. A., Wang, G., Collins, M., Pitsiladis, Y. P. and Williams, A. G.
DOI: 10.1186/s12863­017­0470­1
Example citation: Heffernan, S. M., Stebbings, G. K., Kilduff, L. P., Erskine, R. M.,
Day, S. H., Morse, C. I., McPhee, J. S., Cook, C. J., Vance, B., Ribbans, W. J., Raleigh,
S. M., Roberts, C., Bennett, M. A., Wang, G., Collins, M., Pitsiladis, Y. P. and Williams,
A. G. (2017) Fat mass and obesity associated (FTO) gene influences skeletal muscle
phenotypes in non­resistance trained males and elite rugby playing position. BMC
Genetics. 18(4) 1471­2156. (In Press)
It is advisable to refer to the publisher's version if you intend to cite from this work.
Version: Published version
Official URL: http://dx.doi.org/10.1186/s12863­017­0470­1
Note:
 
This work is licensed under a Creative Commons Attribution 4.0 International License.
http://nectar.northampton.ac.uk/9307/
NE
TA
RESEARCH ARTICLE Open Access
Fat mass and obesity associated (FTO) gene
influences skeletal muscle phenotypes in
non-resistance trained males and elite
rugby playing position
S. M. Heffernan1*, G. K. Stebbings1, L. P. Kilduff2, R. M. Erskine3,4, S. H. Day1, C. I. Morse1, J. S. McPhee12, C. J. Cook2,6,
B. Vance7, W. J. Ribbans5, S. M. Raleigh5, C. Roberts8,9, M. A. Bennett2, G. Wang10, M. Collins11, Y. P. Pitsiladis10
and A. G. Williams1,4
Abstract
Background: FTO gene variants have been associated with obesity phenotypes in sedentary and obese populations,
but rarely with skeletal muscle and elite athlete phenotypes.
Methods: In 1089 participants, comprising 530 elite rugby athletes and 559 non-athletes, DNA was collected
and genotyped for the FTO rs9939609 variant using real-time PCR. In a subgroup of non-resistance trained
individuals (NT; n = 120), we also assessed structural and functional skeletal muscle phenotypes using dual energy x-ray
absorptiometry, ultrasound and isokinetic dynamometry. In a subgroup of rugby athletes (n = 77), we assessed muscle
power during a countermovement jump.
Results: In NT, TT genotype and T allele carriers had greater total body (4.8% and 4.1%) and total appendicular
lean mass (LM; 3.0% and 2.1%) compared to AA genotype, with greater arm LM (0.8%) in T allele carriers and
leg LM (2.1%) for TT, compared to AA genotype. Furthermore, the T allele was more common (94%) in selected
elite rugby union athletes (back three and centre players) who are most reliant on LM rather than total body
mass for success, compared to other rugby athletes (82%; P = 0.01, OR = 3.34) and controls (84%; P = 0.03,
OR = 2.88). Accordingly, these athletes had greater peak power relative to body mass than other rugby
athletes (14%; P = 2 x 10-6).
Conclusion: Collectively, these results suggest that the T allele is associated with increased LM and elite athletic success.
This has implications for athletic populations, as well as conditions characterised by low LM such as sarcopenia
and cachexia.
Keywords: RugbyGene project, IRX3, Lean mass
Background
Fat mass and obesity associated (FTO) is the most
investigated gene in obesity and has complex molecu-
lar mechanisms that are yet to be elucidated. Recent
genome-wide association studies (GWAS) have identi-
fied several common single nucleotide polymorphisms
(SNP) in the human FTO gene associated with obesity,
body mass index BMI; [1], cardiovascular disease and
hypertension [2, 3]. These FTO SNPs, which are in
strong linkage disequilibrium (r2 > 0.80), are located in
a cluster on the first intron of the gene on chromo-
some 16 and consequently exhibit similar obesity-
related traits [4]. Thus, within different FTO variants,
those alleles that have been positively associated with
obesity-related phenotypes are referred to as risk al-
leles, while those negatively associated with such traits
are referred to as protective alleles. Homozygotes for
the minor risk allele consistently demonstrate greater
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BMI and body mass (3-10 kg) in comparison to protective
allele carriers [5, 6]. This greater body mass is likely to be
adipose tissue [7–11], although there exist some sug-
gestions of greater lean mass (LM) in addition to fat
mass [9, 12] and independent of fat intake and physical
activity [9]. This suggests that FTO genotype may be
related to muscle properties and is supported by evi-
dence from a large UK twin study that related FTO
SNPs with body composition while controlling for lean
mass and fat mass (separately and combined). The
authors concluded that FTO SNP associations with
body size were a composite of both lean and fat mass,
not fat mass alone [13].
Environmental lifestyle factors (diet and physical activity)
have also been investigated for FTO gene-environment in-
teractions. Risk allele carriers are more likely to choose a
high fat diet than protective allele carriers [11, 14, 15].
However, with administration of a high protein diet (25%
energy intake) risk allele carriers demonstrated a greater
reduction in body mass, fat mass and percentage body fat
[16], due to greater appetite suppression than in protective
allele carriers [17]. Additionally, physically active risk allele
carriers have a 30% reduction in likelihood of becoming
obese and have 36% less body fat compared to inactive risk
allele carrying individuals [18]. In contrast, data from the
HERITAGE Family Study showed that following 20 weeks
of endurance training, protective allele carriers exhibited
reductions in fat mass three times greater than risk allele
homozygotes [19]. Interestingly, when comparing normal
weight and obese individuals who participate in sport, no
differences in FTO genotype were observed (P = 0.97),
which was contrasted by those not participating P = 0.02;
[20]. Considering the attenuation of FTO-associated obesity
with environmental factors and the greater FTO-associated
LM reported in obese populations [9, 12], investigating LM
and associated phenotypes in healthy, non-obese, non-
resistance trained individuals and habitually trained elite
athletes would be worthwhile.
To date, there have been no investigations of in vivo
skeletal muscle phenotypes in trained or non-resistance
trained populations for associations with FTO genotype.
Eynon et al. [21] investigated FTO rs9939609 in three
European cohorts of power (n = 258; 58.3% elite) and
endurance athletes (n = 266; 57.1% elite) from a variety
of sporting disciplines - but identified no associations.
This lack of association was likely due to the consider-
able differences in physiological demand between the
various athletic disciplines included, plus further variabil-
ity in the standard of athlete. We have recently shown the
ability of genetic research in a single sport with player
roles that differ distinctly, namely rugby union (RU), to
reveal context-specific competitive advantages provided
by particular alleles [22]. Therefore, as RU includes
athletes of remarkably distinct anthropometric and body
composition phenotypes, elite RU provides a unique op-
portunity to investigate FTO in individuals at the extreme
upper end of physical fitness [23].
Therefore, the main aims of the present study were to
(1) investigate any association of FTO rs9939609 with
body composition and muscle structural and functional
parameters in a homogenous, healthy, non-obese non-
resistance trained population (2) investigate whether
FTO rs9939609 genotype differed between elite rugby
athletes and a control population, and/or between RU
player positions. Based on prior data in obese popula-
tions, it was hypothesised that the rs9939609 risk (A)
allele would be associated with greater body mass, fat
mass, BMI, LM, muscle volume and muscle strength in
non-resistance trained individuals. Secondly, for the elite
rugby cohort, it was hypothesised that the FTO A allele
would be overrepresented in player positions typically
requiring greater body and muscle mass while the pro-
tective (T) allele would be more common in positions
requiring a lean phenotype.
Method
Participants
A total of 1089 individuals were recruited and gave writ-
ten informed consent to participate in the present study.
The total sample comprised elite Caucasian male rugby
athletes (n = 530; height 1.85 (0.07) m, mass 101 (14) kg,
age 29 (7) yr, BMI 29.4 (3.7) kg∙m-2; mean (standard de-
viation (SD)) including 73% British, 16% South African,
7% Irish and 4% from other nationalities and non-athlete
Caucasian control participants (male and female; n =
559; height 1.75 (0.10) m, mass 75 (13) kg, age 29 (16)
yr, BMI 24.5 (3.6) kg∙m-2) including 86% British, 12%
South African, 1% Irish and 1% from other nationalities.
Athletes were considered elite if they had competed
regularly (> 5 matches) since 1995 in the highest profes-
sional league in the UK, Ireland or South Africa for RU
or the highest professional league in the UK for rugby
league (RL). Of the RU athletes, 52.7% had competed at
an international level for a “High Performance Union”
(Regulation 16, worldrugby.org) and 43.2% of RL had
competed at international level. All data for the athlete
group’s international status were confirmed as of 1st
June 2016. Furthermore, within the rugby cohort, a sub-
sample (n = 77) were examined for performance-related
muscle phenotypes. Within the control group were a
subgroup of non-resistance trained healthy males (NT;
Table 1). NT participants were aged 18–39 years, had a
BMI 18.5–30 kg∙m-2, had not undertaken any structured
resistance training in the preceding 12 months and had
no history of neurological or musculoskeletal disorders.
Additionally, only those participants undertaking less
than 3 h of low-to-moderate physical activity per week,
assessed via questionnaire [24], were included.
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Procedures
Muscle properties in NT
An isokinetic dynamometer (Cybex Norm, Cybex Inter-
national Inc., NY, USA) was used to assess maximal iso-
metric knee extension (MVCKE) and maximal isometric
knee flexion (MVCKF) torque at knee joint angles of 70°,
80° and 90° (full knee extension = 0°). The angle of peak
torque was taken as the optimal knee joint angle and
used to estimate antagonist muscle co-activation during
MVC, which assumed a linear relationship between
biceps femoris EMG activity and knee flexion torque
[25]. Together with antagonist co-activation, quadriceps
femoris (QF) voluntary activation capacity, determined
using the interpolated twitch technique [26], allowed for
the calculation of net MVCKE torque. Subsequently,
patella tendon moment arm length (dPT) was measured
using dual energy x-ray absorptiometry DXA; [27] and
patella tendon force calculated as net MVCKE torque/
dPT. The contribution of the vastus lateralis (VL) muscle
(MFVL) to patella tendon force was calculated by estimating
the relative physiological cross-sectional area (PCSA) of the
VL as ~21% of the QF [28]. VL muscle architecture (fas-
cicle length, Lf and pennation angle, θ) was measured at
50% of VL length during MVCKE at the optimal knee joint
angle using ultrasound (AU5, Esaote, Italy) and VL fascicle
force estimated as MFVL/cosine θ [29]. At rest, ultrasound
was also used to obtain a series of transverse plane scans at
50% of VL muscle length from the medial to lateral bor-
ders, which were contour matched to determine VL ana-
tomical cross-sectional area [ACSA; 29]. With VL length
and VL ACSA used to estimate VL volume (VVL) as previ-
ously [30]. Subsequently, VL PCSA was calculated as VVL/
Lf and, VL specific force calculated by dividing VL fascicle
force by VL PCSA [29]. Finally, quantification of whole
body and appendicular LM was completed using DXA
(Hologic Discovery: Vertec Scientific Ltd, UK) following a
12 h overnight fast. Participants lay in a supine position,
avoiding any contact between the trunk and the appendicu-
lar mass during a 7 min whole body scanning procedure
(effective dose, 8.4 μSv). Appendicular lean mass was esti-
mated from the DEXA as the total muscle mass of both the
upper and lower limbs, where LM is body mass excluding
fat and bone mass.
Muscle power in RU athletes
Using a portable force platform (Type 92866AA, Kistler,
Germany) peak power output (PPO) was determined
during a bilateral countermovement jump (CMJ) ac-
cording to methods described previously [31]. Body
mass and the vertical component of the ground reac-
tion force during the CMJ (sampled at 1000 Hz) were
used to determine instantaneous velocity and displace-
ment of the participant’s centre of gravity. Instantan-
eous power output was determined using the following
equation: Power (W) = vertical GRF (N) x vertical
velocity of centre of gravity (m · s-1), with the highest
value produced deemed the PPO.
Sample collection and genotyping
Description of all molecular procedures have previously
been described in detail [22]. Briefly, blood (~70% of all
Table 1 Descriptive, morphological and functional characteristics of all participants and genetic frequency, in the non-resistance
trained (NT) cohort
Phenotype All (n = 120) AA (n = 18) AT (n = 58) TT (n = 44) TT + AT (n = 102) P values Additive (Recessive)
Height (m) 1.79 (0.06) 1.80 (0.06) 1.78 (0.07) 1.80 (0.06) 1.79 (0.07) 0.15 (0.48)
Mass (kg) 75.0 (10.0) 81.0 (8.1) 74.2 (10.3) 73.5 (9.6) 73.9 (10.0) 0.03 (0.02)
BMI (kg m-2) 23.4 (2.7) 25.1 (2.6) 23.5 (2.8) 22.6 (2.4) 23.1 (2.6) 0.02 (0.02)
Age (years) 20.6 (2.3) 21.6 (2.8) 20.9 (2.4) 19.7 (1.6) 20.4 (2.1) 0.02 (0.08)
Fat mass (%) 21.5 (5.2) 23.3 (5.5) 21.8 (5.2) 20.3 (4.8) 21.2 (5.1) 0.09 (0.11)
LM (%) 73.5 (5.9) 70.3 (6.3) 73.3 (5.6) 75.1 (5.8) 74.4 (5.6) 0.04 (0.04)
Total appendicular LM (%) 33.4 (3.8) 31.6 (3.5) 33.0 (3.7) 34.6 (3.7) 33.7 (3.7) 0.04 (0.05)
Arm LM (%) 8.5 (1.2) 7.9 (1.0) 8.6 (1.3) 8.7 (1.1) 8.7 (1.2) 0.06 (0.04)
Leg LM (%) 24.8 (2.9) 23.7 (3.1) 24.4 (2.8) 25.8 (2.9) 25.0 (2.9) 0.04 (0.10)
VVL (cm
3) 566 (86) 585 (81) 550 (86) 580 (85) 563 (86) 0.20 (0.61)
VL ACSA (cm2) 21.4 (2.5) 21.9 (2.8) 21.0 (2.4) 21.9 (2.5) 21.4 (2.5) 0.20 (0.86)
VL PCSA (cm2) 71.7 (13.9) 71.2 (13.9) 72.0 (13.7) 71.5 (11.0) 71.8 (12.6) 0.97 (0.61)
Isometric MVCKE torque (N m) 272 (53) 285 (38) 271 (63) 268 (45) 270 (56) 0.50 (0.25)
VL specific force (N∙cm-2) 21.6 (2.6) 22.3 (2.5) 21.6 (2.5) 21.1 (2.8) 21.4 (2.6) 0.50 (0.25)
Data are mean (SD)
BMI, body mass index, LM lean mass, VL vastus lateralis, ACSA anatomical cross sectional area, PCSA physiological cross-sectional area, MVCKE maximal voluntary
contraction, VVL vastus lateralis muscle volume
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samples), saliva (~25%) or buccal swab samples (~5%)
were obtained via the following protocols. Blood was
drawn from a superficial forearm vein into an EDTA tube
and stored in sterile tubes at -20°C until processing. Saliva
samples were collected into Oragene DNA OG-500 col-
lection tubes (DNA Genotek Inc., Ontario, Canada)
according to the manufacturer’s protocol and stored at
room temperature until processing. Sterile buccal swabs
(Omni swab, Whatman, Springfield Mill, UK) were
rubbed against the buccal mucosa of the cheek for ap-
proximately 30 s. Tips were ejected into sterile tubes and
stored at -20°C until processing. DNA isolation and geno-
typing were performed in the MMU, University of Glas-
gow, University of Cape Town (DNA isolation only) and
University of Northampton laboratories. The majority of
samples were processed and genotyped in the MMU
laboratory, including all samples within NT. At MMU and
Glasgow, DNA isolation was performed using the
QIAamp DNA Blood Mini kit and standard spin column
protocol, following the manufacturer’s instructions
(Qiagen, West Sussex, UK). Briefly, 200 μL of whole
blood/saliva, or one buccal swab, was lysed, incubated,
the DNA washed and the eluate containing isolated
DNA stored at 4°C. In Cape Town, DNA was isolated
from whole blood using a different protocol [32] during
which samples were lysed, centrifuged, the DNA
washed and samples stored at -20°C. Genotyping of
DNA isolated in Cape Town was performed in Glas-
gow. At Northampton, DNA was isolated from whole
blood using Flexigene kits (Qiagen). Briefly, samples
were lysed, DNA precipitated and washed, with samples
stored at -20°C.
Genotyping in all three genotyping centres was per-
formed on FTO (rs9939609). Briefly, in the Glasgow labora-
tory 10 μL Genotyping Master Mix (Applied Biosystems,
Paisley, UK), 1 μL SNP-specific TaqMan assay (Applied
Biosystems), 6 μL nuclease-free H2O and 3 μL DNA solu-
tion (~9 ng DNA) were added per well. In the Northamp-
ton laboratory, genotyping was performed by combining 10
μL of Genotyping Master Mix, 8 μL H2O, 1 μL assay mix
with 1 μL of purified DNA (~10 ng). In both laboratories,
PCR was performed using a StepOnePlus real-time
detector (Applied Biosystems). Briefly, after an initial 10
min at 95°C, 40 cycles of denaturation at 92°C for 15 s then
annealing and extension at 60°C for 1 min were used.
Genotyping calls were performed using StepOnePlus soft-
ware version 2.3 (Applied Biosystems). At MMU, 5 μL
Genotyping Master Mix, 4.3 μL H2O, 0.5 μL assay mix and
0.2 μL of purified DNA (~9 ng) were used in each reaction
for samples derived from blood and saliva. For DNA de-
rived from buccal swabs, 5 μL Genotyping Master Mix was
combined with 3.5 μL H2O, 0.5 μL assay mix and 1 μL
DNA solution (~9 ng DNA). Either a Chromo4 (Bio-Rad,
Hertfordshire, UK) or StepOnePlus real-time PCR system
was used. Briefly, after an initial 10 min at 95°C, 40 cycles
of denaturation at 92°C for 15 s then annealing and exten-
sion at 60°C for 1 min were used. Genotyping calls were
performed using Opticon Monitor software version 3.1
(Bio-Rad) or StepOnePlus software version 2.3. The Taq-
man assay included VIC and FAM dyes that indicated A
and T alleles on the forward DNA strand, respectively.
Thus, VIC/FAM were interpreted as: 5′-GTGAATTT[A/T]
GTGATGCA-3′.
RU positional groups
As established previously [22], to compare genotype
and allele frequencies within the RU group, athletes
were allocated to subgroups; forwards (props, hookers,
locks, flankers, number eights) and backs (scrum
halves, fly halves, centres, wings, full backs). Also, due
to diverse physiological demands within RU [33, 34],
athletes were further divided into established pos-
itional groups according to their movement patterns
[33]; front five (props, hookers, locks), back row
(flankers, number eights), half backs (scrum halves, fly
halves), back three (wings and full backs) and centres.
For example, in one study the front five travelled ~136
m at > 5 m · s–1 compared to ~566 m for the back
three [35]. Comparisons between positions were not
performed for the RL cohort due to low statistical
power when it was subdivided.
Data analysis
SPSS for Windows version 22 (SPSS Inc., Chicago, IL)
software was used to conduct statistical analyses. One-
way analysis of variance (ANOVA) was used to compare
height, mass, BMI, age and PPO between sample popu-
lations and genotype groups. When genotype groups
were compared using a recessive model, an independent
samples t-test was used. Furthermore, genotype effects
on muscle phenotypes of interest were assessed for
linear trend. Pearson’s χ2 tests compared genotype and
allelic frequencies between athlete and control groups
and between RU positional subgroups. There were 30
comparisons for genotype frequency between groups
and 28 tests of genotype differences in phenotype in NT
that were subjected to Benjamini-Hochberg corrections
to control false discovery rate and corrected probability
values are reported [36]. Where appropriate, odds ratio
(OR) and eta squared (ηP
2) were calculated to estimate
effect size. Alpha was set at 0.05.
Results
Genotype calling was successful in all samples. There
was 100% agreement among reference samples geno-
typed in the three genotyping centres, i.e. Glasgow,
Northampton and MMU laboratories. Genotype fre-
quencies were in Hardy-Weinberg equilibrium for
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the entire control group (P = 0.871), NT (P = 0.988)
and athlete groups (RL, P = 0.183; RU, P = 0.076).
Non-resistance trained (NT)
The AA genotype group had greater body mass, BMI
and age but not height compared to other genotype
groups (Table 1). There were genotype differences for
total body (ηP
2 = 0.072), total appendicular (ηP
2 = 0.075)
and leg (ηP
2 = 0.078) LM, with tendencies for arm LM (P
= 0.06, ηP
2 = 0.054) and total fat mass (P = 0.09, ηP
2 =
0.024). T-allele carriers demonstrated greater total body
(5.3%), appendicular (6.7%) and arm (9.8%), but not leg
(P = 0.10) LM than AA homozygotes. There were no dif-
ferences in muscle size, torque or specific force variables
(Table 1).
Athletes
Athletes were taller and heavier (P < 0.05) but not older
(P > 0.05) than controls. There were no genotype fre-
quency differences between athletes (RL and RU com-
bined; P = 0.16), RL (P = 0.36), RU (P = 0.16) and controls
(only additive models presented).
In terms of player position, backs had a greater fre-
quency of T allele carriers than forwards (P = 0.03,
Table 2, Fig. 1) and showed greater odds of being T allele
carriers than AA genotype (OR = 1.84, Table 3). When
combined, the back three and centres group contained
less AA homozygotes and more T allele carriers (P =
0.03, P = 0.02, respectively; Fig. 1a and Table 2) than
controls. Additionally, controls had more than twice the
odds of being AA than the back three and centres group,
with greater odds of T allele carriers in the back three
and centres than controls (Table 3). Compared to for-
wards and all other RU athletes, TT genotype (P = 0.03;
P = 0.03, respectively) and T allele carriers (P = 0.02; P =
0.02, respectively) were more common in the back three
and centres group (Fig. 1a and Table 2). Likewise, for-
wards and all other RU athletes had greater than three
times the odds of being AA genotype than the back
three and centres group, with greater odds of T allele
carriers in the back three and centres group than for-
wards and all other RU athletes (Table 3). Furthermore,
the back three and centres group showed a greater T
allele frequency than both forwards and all other RU
athletes (Fig. 1b) and almost one and a half times greater
odds of possessing the T allele (Table 3).
Muscle power
While PPO tended to be greater in back row players
with lowest power in the halfbacks (5792 vs 5000 W; P
= 0.09), PPO relative to body mass did differ according
to playing position (Table 4). The centre and back 3
players (59 W∙kg-1) were 9.8% more powerful than back
row (54 W∙kg-1; P = 0.025) and 20.2% more powerful
than front 5 players (47 W∙kg-1; P = 6 x 10-7; Table 4).
Discussion
We have shown that individuals possessing the FTO
rs9939609 T allele and TT genotype had greater LM,
while no differences in leg muscle size or strength were
observed (Table 1), thus rejecting our first hypothesis
that the risk (A) allele would be associated with greater
LM and muscle volume in a healthy non-resistance
trained population. That greater LM in T allele and TT
genotype individuals was observed despite A allele car-
riers having greater body mass and BMI as reported pre-
viously [5, 6]. In agreement with our second hypothesis,
we report a greater T allele and TT genotype frequency
in elite rugby athlete playing positions more reliant on a
lean phenotype for success [37], while the A allele is
more common in those positions where total body mass
is more important [38]; Fig. 1, Tables 2 and 3. The ability
to rapidly produce high levels of power relative to body
mass using the leg musculature was greater in those
playing positions more reliant on a lean phenotype
(Table 4) and is in agreement with previously published
data of elite RU players [39]. One possible biological
mechanism underlying the present results may be the
action of the iroquois homeobox 3 (IRX3) protein
through its FTO genomic loci interaction.
Table 2 Genotype and allele distribution of controls and athletes separated by code (RL and RU) and into positional subgroups for
RU, presented as genotype/allele counts followed by percentage in parentheses
Genotype/allele All athletes RL athletes RU athletes Controls Forwards Backs Front 5 Back row Half backs Back 3 and centres
FTO
AA 80 (15.1) 12 (13.6) 69 (15.3) 90 (16.1) 48 (18.5) 21 (11.0) 30 (17.0) 18 (21.7) 13 (17.8) 8 (6.8)*
AT 280 (52.7) 49 (55.7) 235 (52.3) 266 (47.6) 133 (51.4) 102 (54.7) 94 (53.4) 39 (47.0) 34 (46.6) 68 (57.6)
TT 170 (32.2) 27 (30.7) 146 (32.4) 203 (36.3) 78 (30.1) 68 (34.3) 52 (29.6) 26 (31.3) 26 (35.6) 42 (35.6)‡
Total 530 88 450 559 259 191 176 83 73 118
A allele 440 (41.5) 73 (41.5) 375 (41.4) 446 (39.9) 229 (44.2) 144 (37.7) 154 (43.7) 75 (45.2) 60 (41.1) 84 (35.6)‡
T allele 620 (58.5) 103 (58.5) 527 (58.6) 672 (60.1) 289 (55.8) 238 (62.3) 198 (56.3) 91 (54.8) 86 (58.9) 152 (64.4)
Eight athletes competed in both elite RL and RU and were included in both groups that were analysed separately. *Different from controls (P < 0.04). ‡Different
from forwards (P = 0.03)
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Until recently, little was known about the molecular
basis for FTO SNP associations with any reported
phenotype measure, because there was no association
between FTO SNPs and expression of the FTO protein
[40, 41]. However, FTO has recently been found to influ-
ence IRX3 protein expression, through evolutionarily
conserved long-range chromatin looping. Individuals
possessing the protective FTO genotype/allele (TT/T)
display lower IRX3 expression than AA homozygotes
[42]. Furthermore, in contrast to IRX3 knockout (KO)
mice, wild type mice exhibited similar FTO SNP risk (A)
allele-associated phenotypes, such as greater BMI, body
mass and body fat percentage [42]. Interestingly, IRX3
KO mice expended more energy, particularly at night,
due to a greater browning of white fatty tissue [42] and
recent findings show a link between brown fat and
muscle developmental precursor Myf5 [43] which may
provide a mechanism for the observation of greater LM
in FTO T allele carriers in our NT cohort. Moreover,
Fig. 1 FTO genotype data of athletes and controls. a Recessive model. Grey bars are T allele carriers, black bars are AA genotypes. b Allele frequency
for selected subgroups. Grey bars represent the T allele, black bars represent the A allele
Table 3 Odds Ratio statistics for RU athlete status by playing
position for FTO genotype (TT/AA), allele (T/A) and recessive
(T/AA) genetic models
Positional comparison Genetic
model
Odds
ratio
95% Confidence
interval
P value
Backs v Forwards T/AA 1.84 1.06-3.19 0.029
Back 3 and centres
v Controls
TT/AA 2.33 1.05-5.16 0.038
T/AA 2.64 1.05-5.16 0.012
Back 3 and centres
v Forwards
TT/AA 3.23 1.39-7.46 0.006
T/AA 3.12 1.43-6.84 0.004
T/A 1.44 1.04-1.97 0.026
Back 3 and centres
v all other RU athletes
TT/AA 3.08 1.36-6.98 0.007
T/AA 3.09 1.43-6.68 0.004
T/A 1.37 1.01-1.86 0.045
Back 3 and centres
v other backs
TT/AA 2.98 1.17-7.59 0.022
T/AA 2.63 0.96-7.19 0.060
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using a transgenic mouse model (Rosa26Enr-Irx3) that
disrupts IRX3 function whilst maintaining the genomic
interaction between IRX3 and FTO (mimicking more
accurately the human in vivo state than the aforemen-
tioned KO model), the authors showed retention of the
KO model phenotype traits [42]. These FTO-IRX3 pro-
tein interactions suggest an explanation for the greater
LM seen with the T allele carriers of the present study
and possibly the association of the T allele with muscle
power relative to body mass and its relationship with
playing position in RU athletes (Tables 1, 2, and 4;
Fig. 1).
The precise mechanisms of action of IRX3 in mamma-
lian physiology are not fully understood, however the
primary role of IRX3 in embryonic development and
future actions in motor neuron restriction is relevant to
this discussion. During neuronal development, IRX3
expression plays a key role in N-tubulin development
and initiation of neuronal programming. High levels of
IRX3 protein promote early tissue development resulting
in a lack of cell differentiation [44]. Thus, it is possible
that because the FTO T allele is associated with lower
IRX3 expression, greater early motor neuron differenti-
ation might subsequently lead to greater LM – as we
observed (Table 1). As such, for predeterminant neuronal
cells to differentiate into a progenitor motor neuron
domain and subsequently motor neurons, it appears IRX3
must be repressed by the microRNA mir-17-3p in order
for OLIG2 to regulate the development of ventral spinal
motor neurons [45]. Thus, as the expression of OLIG2
increases, the yield of motor neurons increases in tandem
[46]. Considering FTO T allele carriers have a lower em-
bryonic expression of IRX3, T allele carriers may have a
predisposition for greater LM through enhanced life-long
motor neuron availability via OLIG2 expression and there-
fore, may be at an advantage for certain forms of athletic
ability and associated performance phenotypes (Tables 2,
3 and 4; Fig. 1). This rationale and the present results may
represent a small portion of the 85% heritability of adult
muscle neuronal function [47].
Recent associations between FTO variants and IGF-1,
specifically that serum IGF-1 levels were greater in T allele
carriers [48], may provide a second mechanism to explain
the observed genotype differences in LM (Table 1). It is
well known that IGF-1 is upregulated as a consequence of
mechanical load/exercise and plays an important role in
the cellular development of muscle hypertrophy [49].
Hence, T allele carriers, who in the NT group had signifi-
cantly greater LM, may experience upregulation of IGF-1
compared to AA genotype counterparts. Furthermore,
serum IGF-1 levels have been positively associated with
quadriceps torque [50] and explosive muscle power [51]
in older men. These data provide a further potential basis
for our observation that RU athletes who require greater
muscle power relative to body mass (Table 4) show a
greater frequency of the T allele than other playing posi-
tions (Table 2 and 3; Fig. 1).
We observed a lower frequency of the AA genotype in
back three and centre playing positions (OR = 2.53;
Table 3), although there was no difference between the
entire rugby cohort and controls. That latter observation
is similar to that we reported previously regarding
another genetic variant (ACTN3 rs1815739) where there
was no difference between the entire rugby cohort and
controls despite differences in genotype frequency ac-
cording to playing position [22]. This again demon-
strates the importance of defining athletes very carefully
when conducting such comparisons. Global positioning
system (GPS) data provide evidence for the relevance of
our finding regarding FTO genotype in elite athletes.
Jones et al. [35] showed that - at an elite competitive
level - the back three and centre players express the
greatest ‘instantaneous and accumulative demands for
exercise’ (exertion index; EI) than all other athletes and
spent more time at sprinting intensities. Thus, there is
congruence between our dual observations of firstly
greater LM in NT associated with the T allele, and sec-
ondly a greater frequency of the T allele in certain elite
rugby athletes who rely on greater power outputs relative
to body mass to be successful in those specific playing po-
sitions Table 3; [39].
These data suggest the relevance of the FTO rs9939609
T allele to muscle-related phenotypes and subsequently,
athletic success. When considering the possible molecular
mechanism from FTO via IRX3 to OLIG2 resulting in
greater lifelong motor neuron availability, this may have
implications for muscle size-related disorders such as
sarcopenia and cachexia.
Conclusions
The presented data show a novel dimension of FTO genetic
variation in human physiology, by investigating in vivo
muscle phenotypes in a healthy non-resistance trained
population and relating those data to the extreme upper
Table 4 Muscle power of RU athletes (n = 77) in positional groups. P values are from comparisons of power between the four
groups. Data are mean (SD)
Phenotype Front 5 (n = 32) Back row (n = 14) Half backs (n = 14) Back 3 and centres (n = 17) P value
Power (W) 5592 (819) 5687 (858) 4937 (650) 5579 (569) 0.030
Relative Power (W∙kg-1) 49.4 (7.7) 52.7 (6.9) 56.1 (7.2) 59.8 (4.2)* 2 x 10-5
*Different from all other players (P = 8 x 10-7), including front 5 (P = 3 x 10-6) and back row (P = 0.005)
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end of human physical performance – i.e. elite athletes. We
show that the FTO rs9939609 protective T allele may be re-
sponsible for part of the inherited component of the inter-
individual variability in LM. Furthermore, elite athletes who
rely greatly on LM relative to total body mass for athletic
success (RU back three and centre players, in this study)
also seem more likely to carry a protective T allele, have
higher peak muscle power output relative to body mass
and are likely to selected for appropriate playing positions
as a result of these and other phenotypes. It is possible that
this association between the FTO rs9939609 SNP, via LM,
and athletic success, could be a result of the interaction
with IRX3 in embryonic development of motor neuron pat-
terning and the IGF-1 muscle development pathway. The
strengths of the presented paper are the two-layered study
design (NT and elite athlete cohorts) and the combination
of muscle functional phenotypes with case-control data.
While the finding that FTO genotype differs among elite
rugby playing positions is a new insight, FTO is only one of
many variants (most others unknown) that contribute to
this phenotype and as such should not be used for talent
identification at this time. Replication is necessary for each
cohort using comparable methods, and future experimental
focus should be on the proposed biological pathways of
these FTO associations with muscle phenotypes.
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